Checkpoint inhibitors in AML: are we there yet?
2019
Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells - CTLA-4 and PD-1 - and PD-L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
81
References
14
Citations
NaN
KQI